Seeking Alpha

Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par...

Somaxon Pharmaceuticals (SOMX) settles its patent litigation suit with Mylan (MYL) and Par Pharmaceutical (PRX) involving Silenor 3 mg and 6 mg tablets. The settlement grants MYL the exclusive right to begin selling a generic version of Silenor on January 1, 2020, and PRX the right to begin selling a generic version 180 days after a third party generic version is first sold in the U.S. under a license from Somaxon.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|